Clinical and Endocrine Effects of the Oral Aromatase Inhibitor Vorozole in Postmenopausal Patients with Advanced Breast Cancer

Cancer Research

Volumn 54, Issue 22, 1994, Pages 5875-5881

  Johnston, Stephen R D ^a   Smith, Ian E ^a   Doody, Deborah ^a   Jacobs, Stephen ^a   Robertshaw, Hazel ^a   Dowsett, Mitchell ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANALGESIC AGENT; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; FOLLITROPIN; HYDROCORTISONE; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; OPIATE DERIVATIVE; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE; THYROTROPIN; THYROXINE; VOROZOLE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; IMMUNORADIOMETRIC ASSAY; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TREATMENT OUTCOME; TRIAZOLES;

EID: 0028077626     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Muhlblock, O., Role of hormones in the etiology of breast cancer. J. Natl. Cancer Inst. 48: 1213-1220, 1972.
2. Santen, R. J., Santner, S., Davis, B. Veldhuis, J., Samojlik, E., and Ruby, E., Aminoglutethimide inhibits extraglandular oestrogen production in postmenopausal women with breast carcinoma. J. Gin. Endocrinol. Metab. 47: 1257-1265, 1978.
3. Santen, R. J., Worgul, T. J., Samojlik, E., Interrante, A. Boucher, A E. Lipton, A., Harvey, H. A., White, D. S., Smart, E., Cox, C., and Wells, S., A A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N. Engl. J. Med. 305: 545-551, 1981.
4. Smith, I. E., Harris, A. L., Morgan, M., Ford, H. T., Gazet, J. C., White, H., Parsons, C. A., Villardo, A., Walsh, G., and McKinna, J., A Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomised cross-over trial. Br. Med. J. 283: 1432-1434, 1981.
5. Harris, A. L., Dowsett, M., Jeffcoate, S. L., and Smith, I. E., Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur. J. Cancer Clin. Oncol. 19: 493-498, 1983.
6. Coombes, R. C., Goss, P., Dowsett, M. Gazet, J. C., and Brodie, A.M.H. 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet, if: 1237-1239, 1984.
7. Goss, P. E., Powles, T. J., Dowsett, M., Hutchinson, G. Brodie, A.M.H. Gazet, J.C., and Coombes, R. C., Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res. 46: 4823-4826, 1986.
8. Stein, R. C., Dowsett, M., Hedley, A. Gazet, J. C., Ford, H. T., and Coombes, R. C., The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer, 62: 679-683, 1990.
9. Schieweck, K., Bhatnager, A. S., and Matter, A., CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. Cancer Res. 48: 834-838, 1988.
10. Stein, R. C., Dowsett, M., Davenport, J. Hedley, A., Ford, H. T., Gazet, J. C., and Coombes, R. C., Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A Cancer Res. 50: 1381-1384, 1990.
11. Lipton, A., Harvey, H. A., Demers, L. M., Hanagan, J. R., Mulagha, M. T., Kochak, G. M., Fitzsimons, S., Sanders, S. I., and Santen, R. J., A phase I trial of CGS 16949A: a new aromatase inhibitor. Cancer (Phila.), 65: 1279-1285, 1990.
12. Dowsett, M., Cunningham, D. Powles, T. J., Hutchinson, G., Brodie, A.M.H., Ford, H. T., Gazet, J. C., and Coombes, R. C., Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandostenedione in postmenopausal breast cancer patients. Cancer Res. 49: 1306-1312, 1989.
13. Raats, I. I., Falkson, G., and Falkson, H. C., A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced breast cancer. J. Clin. Oncol. 10: 111-116, 1992.
14. Dowsett, M., Stein, R. C., Mehta, A., and Coombes, R. C., Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin. Endocrinol. 32: 623-634, 1990.
15. Wouters, W., DeCoster, R. Krekels, M., van Dun, J., Beerens, D. Haelterman, C., Raeymakers, A. Freyne, E., van Gelder, J., Venet, M., and Janssen, P.A.J. R76713, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. 32: 781-788, 1989.
16. Wouters, W., DeCoster, R., van Dun, J., Krekels, M.D.W.G. Dillen, A., Raeymakers, F. Freyne, E., van Gelder, I., Sanz, G. Venet, M., and Janssen, M., Comparative effects of the aromatase inhibitor R76713 and its enantiomers on steroid biosynthesis in rat cells in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 36: 1049-1054, 1990.
17. Krekels, M.D.W.G. Wouters, W., Van Ginckel, R., Janssens, B. Callens, M., and De Coster, R., Aromatase inhibition by R83842, the dextro-isomer of R76713, in JEG-3 choriocarcinoma grown in ovariectomized nude mice. J. Steroid Biochem. Mol. Biol. 41: 761-764, 1992.
18. Wouters, W., van Ginckel, R., Krekels, M. Bowden, C., and DeCoster, R., Pharmacology of Vorozole. J. Steroid Biochem. Mol. Biol. 44: 617-621, 1993.
19. Borms, M., Vandebroek, J. Rutten, J., Tytgat, J. DeCoster, R., Langenaeken, C., and Bruynseels, J., Vorozole-racemate (R76713): a specific non-steroidal aromatase inhibitor pilot study in advanced postmenopausal breast cancer. Eur. J. Cancer, 29(A) (Suppl. 6); S84, 1993.
20. Van der Wall, E., Donker, T. H., DeFrankrijker, E., Nortier, H.W.R., Thijssen, J.H.H. and Blankenstein, M. A., Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res. 53: 4563-4566, 1993.
21. Goes, P. E., Clark, R., Ambus, U. Wiezel, H., Crump, M. Martel, M., Wadden, N. Shepherd, F., Walde, D. Tye, L., and DeCoster, R., Phase II Report of vorozole (R83842), a new aromatase inhibitor in postmenopausal women with breast cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet. Vol. 13, A156: 88, 1994.
22. Vinholes, J., Paridaens, R. Piccart, M. J., Nooij, M., Klijn, J.M.G. Rubens, R. D., Beex, L.V.A. Van Vreckem, A., and Tromiak, E., An EORTC Breast Group Phase II Study of vorozole (R83842), a new aromatase inhibitor in advanced breast cancer (ABC). Proc. Am. Soc. Clin. Oncol. Annu. Meet. Vol. 13, A223: 105, 1994.
23. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A., Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
24. European Organisation for Research and Treatment of Cancer. Cancer-related pain and analgesic score. In: Manual for Clinical Research in Breast Cancer, EORTC Breast Cancer Co-Operative Group, 1991.
25. Haywaid, J. L., Carbone, P. P., Heuson, J.C., Kumoaka, S., Segaloff, A., and Rubens, R. D., Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer, 13: 89-94, 1977.
26. Dowsett, M., Goss, P. E., Powles, T. J., Hutchinson, G., Brodie, A.M.H. Jeffcoate, S. L., and Coombes, R. C., Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 47: 1957-1961, 1987.
27. Dowsett, M., Mehta, A. Mansi, J., and Smith, I. E., A dose-comparative endocrine clinical study of leuporelin in premenopausal breast cancer patients. Br. J. Cancer, 62: 834-837, 1990.
28. Trunet, P. F., Meuller, P., Girard, F. Aupetit, B., Bhatnager, A. S., Zognbi, F., Ezzet, F., and Manard, J., The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J. Clin. Endocrinol. Metab. 74: 571-576, 1992.
29. Jordan, V. C., Fritz, N. F., and Tormey, D. C., Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. 47: 4517-4519, 1987.
30. De Coster, R., Van Ginckel, R. F., Callens, M.J.L. Goeminne, N.K.G. and Janssens, B.L.E. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res. 52; 1240-1244, 1992.
31. De Coster, R., Wouters, W. Bowden, C. R., VandenBossche, J., Bruynseels, J. Tuman, R. W., Van Ginckel, R., Snoeck, E. Van Peer, A., and Janssen, P.A.J. New nonsteroidal aromatase inhibitors: focus on R76713. J. Steroid Biochem. Mol. Biol. 37: 335-341, 1990.
32. Iveson, T. J., Smith, I. E., Ahern, J., Smithers, D. Tninet, P. E., and Dowsett, M., Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53: 266-270, 1993.
33. Harris, A. L., Dowsett, M., Smith, I. E., and Jeffcoate, S. L., Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br. J. Cancer, 47: 621-627, 1983.
34. Wouters, W., De Coster, R., Beerens, D. Doolaege, R., Gruwez, J. A., Van Camp, K., Vanderpas, H., and Van Herendael, B., Potency and selectivity of the aromatase inhibitor R76713; a study in human ovarian, adipose stroma], testicular and adrenal cells. J. Steroid Biochem. Mol. Biol. 36: 37-65, 1990.
35. Howell, A., Mackintosh, I., and Jones, M., The definition of the ‘no-change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur. J. Cancer Clin. Oncol. 24: 1567-1572, 1988.
36. Coombes, R. C., Hughes, S.W.M. and Dowsett, M. 4-Hydroxyandrostenedione: a new treatment for post-menopausal patients with breast cancer. Eur. J. Cancer, 28A: 1941-1945, 1992.
37. Johnston, S.R.D. Smith, I. E., King, N., and Dowsett, M., Oestrogen receptor expression and function in tamoxifen resistant breast cancer. Breast, 2: 193, 1993.